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Introduction: The association between cancer and use of biologic therapy among rheumatoid arthritis (RA)
patients remains controversial. We aimed to compare the relative risk of cancer development between RA patients
taking tumor necrosis factor α (TNFα) antagonists and those taking nonbiologic disease-modifying anti-rheumatic
drugs (nbDMARDs).
Methods: We conducted a nationwide cohort study between 1997 and 2011 using the Taiwan National Health
Insurance Research Database. The risk of newly diagnosed cancer was compared between patients starting TNF-α
antagonists (biologics cohort) and matched subjects taking nbDMARDs only (nbDMARDs cohort). Cumulative
incidences and hazard ratios (HR) were calculated after adjusting for competing mortality. Standardized incidence
ratio (SIR) was calculated for cancer risk. Multivariate analyses were performed using Cox proportional hazards model.
Results: We compared 4426 new users of TNF-α antagonists and 17704 users of nbDMARDs with similar baseline
covariate characteristics. The incidence rates of cancer among biologics and nbDMARDs cohorts were 5.35 (95%
confidence interval (CI) 4.23 to 6.46) and 7.41 (95% CI 6.75 to 8.07) per 1000 person-years, respectively. On modified
Cox proportional hazards analysis, the risk of cancer was significantly reduced in subjects in biologics cohort
(adjusted HR 0.63, 95% CI 0.49 to 0.80, P < .001), after adjusting for age, gender, disease duration, major
co-morbidities, and prior use of DMARDs and corticosteroids. However, there was an increased risk for hematologic
cancers in biologics cohort, yet without statistical significance. The effect of biologics was consistent across all
multivariate stratified analyses and the association between biologics use and cancer risk was independent of
dosage of concomitant nbDMARDs.
Conclusion: These findings suggested that RA patients taking TNF-α antagonist are associated with a lower risk of
cancer, but not for hematologic cancers, than RA patients taking nbDMARDs alone.Introduction
Rheumatoid arthritis (RA) affects both patient psych-
ology and physiology, including cardiovascular, musculo-
skeletal and respiratory systems, and leads to major
comorbidities and mortality. RA is associated with cer-
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stated.an increased incidence of lymphoma [1,3,5-7] and de-
creased incidence of colorectal and gastric cancer in RA
patients [6]. Cancer risk may be related to disease severity
and treatment options. For example, the risk of lymphoma
is substantially increased in those with high disease activity
[8]. On the contrary, non-steroidal anti-inflammatory
drugs (NSAIDs) have been reported to be associated with
a reduced risk of colon cancer [9,10]. Traditional disease-
modifying anti-rheumatic drugs (DMARDs) may also
increase the risk of malignancy. For example, discontinu-
ation of methotrexate has been followed by the disappear-
ance of lymphoma in some patients [11].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ment of RA has raised concerns about the risk of cancer,
particularly with respect to anti-TNF therapies, due to
the role of TNF in tumor progression and surveillance
[12]. An experimental animal tumor model has shown
that anti-TNF-α antibodies hinder the innate anti-tumor
immune responses and promote the growth of immuno-
genic rat colon tumors that are rejected by immunocom-
petent untreated rats. It has been suggested that biologics
dampen the immune response against normally regressing
cancers, thereby fostering malignant growth [13]. The evi-
dence for the association between cancer occurrence and
biologic use is conflicting. Systematic review and meta-
analyses of clinical trial data have revealed an increased
short-term risk of certain cancers in patients taking TNF
inhibitors [14,15]. On the contrary, a recent meta-analysis
of 63 randomized controlled trials demonstrated no asso-
ciation between the use of biologics and cancer risk in RA
patients [16,17]. To date, only a few observational studies
have been conducted on this issue, with controversial re-
sults on the long-term cancer risk among users of bio-
logics with RA [18,19].
Here, we aimed to compare the cancer risk among RA
patients starting TNFα blocker and those taking nonbio-
logic disease modifying antirheumatic drug (nbDMARD)
in a large cohort of patients with RA, based on a
Taiwanese nationwide database.Methods
Study design
We conducted a nationwide cohort study by retrieving
all patients with a diagnosis of RA from Taiwan’s Na-
tional Health Insurance Research Database (NHIRD).
The NHIRD has been used extensively in epidemiologic
studies in Taiwan [3,20]. In brief, it consists of detailed
health care data from more than 25 million enrollees,
representing more than 99% of Taiwan’s entire population.
In this database, the diagnostic codes are in the format of
the International Classification of Diseases, Revision 9,
Clinical Modification (ICD-9-CM). Patients were diag-
nosed by board-certified physicians in the corresponding
specialties. The accuracy of diagnosis of major diseases in
the NHIRD, such as stroke and acute coronary syndrome,
has been validated. Personal information including body
weight, height, family history, laboratory examination re-
sults, lifestyle and habits such as smoking and alcohol use
was not available from the NHIRD.
This study has been approved by the ethical review board
of the Taichung Veterans General Hospital, Taichung,
Taiwan. As the datasets used in this study consist of de-
identified secondary data released to the public for research
purposes, no consent was needed for the review by the eth-
ical review board.Biologic therapy in the RA cohort
Biologics were first introduced for RA management in
Taiwan in March 2003. Biologics available for RA treat-
ment in Taiwan include TNF-α inhibitors (adalimumab,
etanercept and golimumab) and chimeric anti-CD20
monoclonal antibody (rituximab). Other classes of bio-
logics, including humanized IL-6 receptor antibody (toci-
lizumab, or Actemra®) and selective T-cell co-stimulatory
modulator (abatacept, or Orencia®), were not covered
under the NHI program until mid 2012. Golimumab was
not introduced to Taiwan until 1 January 2012. Therefore,
none of the patients included in the present study were
treated with golimumab, tocilizumab or abatacept.
Under the NHI program, only RA patients with continu-
ous and active disease (fulfilling 1987 American College of
Rheumatology (ACR) criteria for RA [21], with disease ac-
tivity score 28-joint assessment (DAS 28) >5.1 points at
least twice, recorded at least one month apart, and with
radiologic and laboratory evidence) and who failed to re-
spond to at least 6 months treatment with more than two
nbDMARDs (mainly methotrexate, cyclosporine, hydro-
xychloroquine, D-penicillamine, gold salts, et cetera),
can apply for reimbursement for biologics. Patients with
prior history of pre-malignant or malignant diseases in
the past 10 years or those with active infection are not
eligible for biologics [22]. Information on medications
was retrieved from the pharmacy prescription database.
Reliability of the retrieved information was independ-
ently verified by two statisticians.
Study cohorts
All patients with a primary diagnosis of RA (ICD-9-
CM code 714.0) for the first time and who received
nbDMARDs or biologics, including TNFα antagonists and
rituximab, between 1997 and 2011 were eligible study sub-
jects. The diagnostic accuracy of RA was confirmed by
both specific ICD-9 codes and inclusion in the Registry for
Catastrophic Illness Patient Database (RCIPD), a subpart
of the NHIRD. As previously described, clinical and la-
boratory confirmation or typical image presentation of RA
is required for patients to be registered in the RCIPD [3].
Identification and definition of study groups
Patients who received TNFα antagonist, adalimumab or
etanercept, or rituximab for RA, were eligible for inclu-
sion in the biologics group. Patients taking nbDMARDs
and who had never received prescription for biologics
were eligible for inclusion in the nbDMARDs group. We
created a matched sample by matching biologics and
nbDMARDs subjects by date of birth, age at first use of
DMARDs, gender, concomitant comorbidities, duration
of disease, and starting date of study, as described below.
Follow up began on the date that a patient added or
switched to a TNF-α antagonist (adalimumab or etanercept;
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tuximab. A matched calendar date as the index date was
determined in matched nbDMARD subjects. Only when
the index date is determined can we include those having
no history of malignancies before or 6 months after the
index date from the eligible nbDMARDs cohort. Finally, we
selected matched patients in the nbDMARDs cohort
fulfilling all of these criteria, including age, gender, co-
morbidities and those listed above. All participants were
observed for the occurrence of outcomes, until death,
or 31 December 2011. To study the patients with active
disease requiring long-term disease control, we included
only those who received nbDMARDs or biologics for at
least 3 months after the start of follow up (the index
date). Patients receiving follow up for less than 6 months
were not included. Patients with history of malignant
disease (ICD-9-CM codes: 140–208, ICD-O-3 codes:
C00-C80) before or during the 6 months following the
index date were not included.
Main outcome measurements
Patients with cancer were defined as those having a new
diagnosis of cancer (ICD-9-CM codes: 140–208, ICD-O-
3 codes: C00-C80) at least 6 months after the index date.
To reduce the mixed effect of prior use of nbDMARDs
and new biologics, diseases of outcome diagnosed during
the first 6 months of observation were not included.
Identification of cancer cases
We identified the diagnoses of cancers based on the re-
cords of the RCIPD. To apply for a cancer catastrophic
illness certificate, cytological or pathological reports or
evidence including additional laboratory and imaging
studies supporting the diagnosis of cancer, such as tumor
marker surveys, radiograph, bone scan, computer tomog-
raphy (CT) scan or magnetic resonance imaging (MRI)
scan, must be provided. At least two other oncologists
carefully examine the medical records and laboratory in-
formation including imaging studies. Only those patients
who meet the criteria of diagnoses are issued certificates.
We excluded those with in-situ malignancies, as in-situ
malignant diseases do not qualify for a catastrophic illness
certificate. The diagnostic codes of malignancies were de-
fined as those from 140 to 208.91 in the ICD-9 revision
clinical modification format (ICD-O-3 codes: C00-C80).
We categorized the cancer cases into hematologic cancers
and non-hematologic cancers. Hematologic cancers were
subcategorized into leukemias (ICD9-CM codes 204 to
208; ICD-O3 codes: 9811 to 9818, 9820, 9823, 9826, 9827,
9831 to 9837, 9840, 9860 to 9861, 9863, 9865 to 9867,
9869, 9870 to 9876, 9891, 9895 to 9898, 9910, 9911, 9920,
9930, 9945, 9946, 9963, 9742, 9800, 9801, 9805 to 9809,
9931, 9940, 9948, 9964) and lymphomas (including non-
Hodgkin’s lymphoma, multiple myeloma (ICD9-CM codes200, 202 to 203; ICD-O-3 codes 9590, 9591, 9596, 9597,
9670, 9671, 9673, 9675, 9678 to 9680, 9684, 9687 to 9691,
9695, 9698, 9699, 9701, 9702, 9705, 9708, 9709, 9712,
9714, 9716 to 9719, 9724 to 9729, 9735, 9737, 9738,
9732 to 9733) and Hodgkin’s lymphoma (ICD9-CM
code 201; ICD-O-3 codes 9650 to 9655, 9659, 9663 to
9665, 9667)), according to the methods of the Cancer
Registry in Taiwan.
Potential confounders
Certain demographic factors, such as age at first use of
nbDMARDs, gender, and comorbidities such as hyper-
tension, ischemic heart disease, including myocardial
infarction, diabetes, cerebrovascular disease, and chronic
liver disease, including liver cirrhosis, were considered
potential confounders. These variables were determined
over a one-year period before the start of follow up.
Other confounders included use of nbDMARDs, use
of corticosteroids, and use of NSAIDs including aspirin,
one year prior to the index date, as listed in Table 1. The
use of statins and metformin have been reported to affect
the development of certain cancers [23,24], and were also
considered covariates.
No information on several potential confounders was
available, such as smoking, alcohol use, family history,
body mass index, rheumatoid arthritis activity, labora-
tory status, and educational level.
Statistical analysis
The demographic data of the study population were first
analyzed. Follow up for each subject was measured in
numbers of years and began on the date of first prescrip-
tion of biologics in the biologics group (or the matching
calendar date in the nbDMARDs group) and ended on
the date of censorship, that is, the date of diagnosis of
outcome, death, transfer out or the end of the follow-up
period.
As death may result from underlying illness, which
may also affect the outcome, it leads to informative cen-
soring in the estimation of the incidence of outcome dis-
eases. Therefore, death occurring prior to outcome was
considered a competing risk event. The cumulative inci-
dence of newly diagnosed cancers after adjustment for
competing mortality was calculated using a two-step
process and tested for equality among the study cohorts.
Calculation and comparison of cumulative incidence in the
presence of competing risk data ratios was conducted
using a modified Kaplan-Meier method and Gray’s method
[25]. We tested the differences in the full time-to-event dis-
tributions between the study groups using the log-rank
test. The assumption of proportional hazards was con-
firmed by plotting the graph of the survival function versus
the survival time and the graph of the log (−log(survival))
versus the log of survival time.
Table 1 Demographic characteristics of matched study cohorts
Characteristics Biologics nbDMARDs P-value
(n =4,426) (n =17,704)
Age, y, mean (SD) 53.88 (13.08) 53.89 (13.09) 0.97
Female gender, n (%) 3813 (86.20) 15252 (86.20) 1.00
Disease duration before index date, y, median (Q1, Q3) 9.21 (6.84, 11.23) 9.20 (6.81, 11.20) 0.70
Follow-up duration, y, median (Q1, Q3) 3.30 (2.00, 5.39) 3.25 (1.95, 5.29) 0.14
Outcome
Cancer, n (%) 89 (2.00) 486 (2.70) 0.001
Death before outcome, n (%) 192 (4.30) 933 (5.30) <0.001
Overall observation person-years 16650.63 65587.93
Cancer, incidence rates (95% CI) per 1000 person-years 5.35 (4.23, 6.46) 7.41 (6.75, 8.07) <0.005
Number of visits per year during follow ups, median (Q1, Q3) 13.33 (11.61, 14.81) 6.04 (3.15, 9.3) <0.001
Co-morbidities, n (%)
Hypertension 1418 (32.0) 5672 (32.0) 1.00
Chronic liver disease 813 (18.4) 3252 (18.4) 1.00
Ischemic heart disease 496 (11.2) 1984 (11.2) 1.00
Diabetes 388 (8.8) 1552 (8.8) 1.00
Cerebrovascular disease 96 (2.2) 384 (2.2) 1.00
Prior drug use, n (%)1
Methotrexate 4125 (93.2) 8659 (48.9) <0.001
Sulfasalazine 3276 (74.0) 8531 (48.2) <0.001
Hydroxychloroquine 3515 (79.4) 10976 (62.0) <0.001
Glucocorticosteroids 4003 (90.4) 12875 (72.7) <0.001
Other systemic drugs use, n (%)2
Statin 433 (9.8) 2069 (11.7) <0.001
Metformin 264 (6.0) 1096 (6.2) 0.60
NSAID 4349 (98.3) 17041 (96.3) <0.001
Beta-blockers 1115 (25.2) 4337 (24.5) 0.35
Average dosage of certain DMARDs during follow up, each user, mean (SD)3
Methotrexate 9.1(4.32) 6.25 (4.31) <0.001
Sulfasalazine 822.11(652.64) 720.69 (575.53) <0.001
Hydroxychloroquine 194.71(137.37) 187.2 (123.95) <0.001
Glucocorticosteroids 4.42 (3.6) 3.02 (3.21) <0.001
1Drug users indicate patients using drugs within one year prior to the index date. 2Use of drugs at least once per month on average during follow up. 3The
average dosage is depicted as mg/day for all these drugs, except methotrexate (mg/week). DMARDs, disease modifying anti-rheumatic drugs; N, number; NSAID,
non-steroidal anti-inflammatory drugs including aspirin and Cox-2 inhibitors; Q, quartile.
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model in the presence of a competing risk event to
examine the independent association between newly di-
agnosed cancers and use of biologics [25,26]. Assess-
ment of goodness-of-fit of the models with the step-
down method was carried out to analyze the independ-
ent risk factors. The influence of biologics on newly
diagnosed cancer was further explored by stratification
according to age, gender, disease duration, time from
start of follow up, and prior use of DMARDs or
corticosteroids.Sensitivity analyses included (1) focusing on individ-
uals who used adalimumab only; ever used adalimumab;
or last use of adalimumab before cancer occurrence; and
(2) focusing on individuals who used etanercept only;
ever used etanercept; or last use of etanercept before
cancer occurrence. These sensitivity analyses were con-
ducted with the purpose of examining whether the main
findings were robust to different assumptions.
All data management was performed using SAS 9.2
software (SAS Institute Inc., Cary, NC, USA). Calculations
of cumulative incidences and Cox models were carried
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were expressed as the estimated number together with the
95% CI.
Results
Demographic characteristics of study cohorts
We identified 47,531 potentially eligible RA patients
from the RCIPD. A total of 2,763 patients who never re-
ceived DMARDs were excluded. Among the remaining
44,768 subjects, 6,871 patients with a history of biologics
use including TNFα antagonists and rituximab were eli-
gible for inclusion in the biologics group and the remaining
37,897 patients who had never used biologics were eligible
to be included in the nbDMARDs group. We excluded
2,445 patients in the eligible biologics group who received
biologics or traditional DMARDs for less than 3 months;
or were followed up for less than 6 months, after starting
biologics treatments. Next, we matched four subjects in
the eligible nbDMARDs cohort with each subject in the bi-
ologics cohort, based on the matching criteria listed in
Methods. Finally, the biologics group and the nbDMARDs
group consisted of 4,426 and 17,704 patients, respectively,
as shown in Figure 1.
The biologics group and nbDMARDs group were
similar in demographic characteristics and associated
comorbidities (Table 1). In the biologics group, 3,27047531 RA patients were identified from the RCIPD in the 
NHIRD.
2763 excluded due to never using DMARDs 
44768 RA patients who ever used DMARDs
6871 in biologics cohort
37897 in non-biologic DMARD cohort
1:4 matching by sex, comorbidities, date of birthday and the 
first date of DMARDs use. (All patients fulfilled: used 
DMARDs for more than 3 months and followed up for more 
than 6 months, without prior cancer diagnosis)
4426 in biologics cohort
17704 in non-biologic DMARD cohort
2445 excluded in biologic cohort due to use of 
DMARDs or biologics less than 3 months or 
followed up for less than 6 months
Figure 1 Flow chart of study subject selection. RA, rheumatoid
arthritis; RCIPD, Registry for Catastrophic Illness Patient Database;
NHIRD, Taiwan National Health Insurance Research Database;
DMARD, disease-modifying anti-rheumatic drug.patients (73.9%) received etanercept, 1,577 patients
(35.6%) received adalimumab and 578 patients (13.1%)
received rituximab. There were 2,529 patients who re-
ceived etanercept only, 996 patients who received adali-
mumab only, and 10 patients who received rituximab
only. It is not uncommon for biologics to be switched.
For example, 323 patients switched from adalimumab to
etanercept; 310 patients switched from etanercept to ri-
tuximab; 150 patients switched from adalimumab to ri-
tuximab; and 108 patients switched treatment among all
three biologics.
Disease duration, mean observation time, and number
of hospital visits are presented in Table 1. Subjects in
the biologics group took more DMARDs and corticoste-
roids than those in the nbDMARDs group before the
index date (Table 1). In addition, more than 92% of pa-
tients in the biologics group received biologics in com-
bination with nbDMARDs or corticosteroids after the
index date. The average daily dosages of combined non-
biologic DMARDS in the biologics group were higher
than in the nbDMARDs group (Table 1, Additional
file 1: Table S1).
Incidence rates of newly diagnosed cancers
A total of 89 patients in the biologics group and 486 pa-
tients in the nbDMARDs group presented with newly di-
agnosed cancer during the observation period. The 7-
year cumulative incidence of newly diagnosed cancer
after adjusting for competing mortality was significantly
lower in the biologics group (3.84%, 95% CI 2.91, 4.77)
than in the nbDMARDs group (5.22%, 95% CI 4.69,
5.75) (P =0.005), as shown in Figure 2.
The incidence rates of newly diagnosed cancer were
estimated to be 5.35 per 1000 patient-years (95% CI 4.23,
6.46) in the biologics group and 7.41 per 1000 patient-
years (95% CI 6.75, 8.07) in the nbDMARDs group, with
statistically significant difference (Table 2). No cancer
cases were observed among those taking rituximab alone.
The cancer risk was lower in those taking adalimumab
alone, when compared with those taking etanercept alone,
but without statistical significance.
Multivariate analysis after adjustment for competing
mortality
When compared with the use of nbDMARDs, starting of
TNF-α antagonists was associated with a significantly re-
duced risk of cancer (adjusted HR 0.63, 95% CI 0.49, 0.80,
P <0.0001), after adjusting for age, gender, disease dur-
ation, number of hospital visits, prior use of DMARDs,
prior use of systemic corticosteroids, and presence of dia-
betes, hypertension, ischemic heart disease, cerebrovascu-
lar disease, or chronic liver disease (Table 3).
Use of statins, use of metformin, use of beta-blockers,
long disease-duration and presence of ischemic heart
Figure 2 Cumulative incidences of new cancer occurrence following initiation of biologics after adjustment for competing mortality.
Calculation and comparison of cumulative incidences in the presence of competing risk data ratios were conducted using a modified
Kaplan-Meier method and Gray’s method. New cancer occurrence during the first six months was excluded. DMARDs, disease-modifying
anti-rheumatic drugs.
Wu et al. Arthritis Research & Therapy 2014, 16:449 Page 6 of 12
http://arthritis-research.com/content/16/5/449disease were also associated with a lower risk of cancer.
On the contrary, increasing age and higher average num-
ber of hospital visits were significantly associated with
cancer occurrence (Table 3).
Multivariate stratified analyses after adjustment for
competing mortality
We conducted multivariate stratified analyses adjusted
for competing mortality to determine the effects of bio-
logics on cancer development among different subsets of
RA patients. A negative association between biologics use
and cancer occurrence was observed in almost all subsets
of study subjects, especially among those of older age, ofTable 2 Multivariate analyses of risk of malignant diseases am
All TNF-α inhibi
Biologics Event, number 89 89
Total person-years 16650.63 16624.36
IR per 1000 (95% CI) 5.35 (4.23, 6.46) 5.35 (4.24, 6.4
nbDMARDs4 Event, number 486 485
Total person-years 65587.93 65485.91
IR per 1000 (95% CI) 7.41 (6.75, 8.07) 7.41 (6.75, 8.0
HR (95% CI) 0.63 (0.49, 0.80) 0.63 (0.50, 0.8
IRR (95% CI) 0.72 (0.58, 0.90) 0.72 (0.58, 0.9
P-value 0.0046 0.0049
1Includes all patients who have used TNF-α inhibitors, with or without disease-mod
matched controls. 2Use of adalimumab alone, with or without DMARDs or corticost
without DMARDs or corticosteroids, in comparison with matched controls. 4Indicate
THE nonbiologic DMARDS (nbDMARDs) cohort for each of those using different typ
incidence rate ratio.female gender, with long-disease duration, and free of co-
morbidities (Figure 3).
To examine the potential mixed effect of DMARDs or
corticosteroids on cancer risk in biologics users, we
further conducted analyses by stratifying the dose of
concomitant DMARDs. The association between bio-
logics use and cancer risk was independent of daily dos-
age of concomitant nbDMARDs.
Specific cancer risks and sensitivity analyses by
standardized incidence ratio (SIR)
Sensitivity analyses focusing on patients receiving differ-
ent treatment patterns of TNF-α inhibitors is presentedong biologic users in comparison with matched controls
tor 1 users Adalimumab2 Etanercept3 Rituximab
8 71 0
2203.45 10363.75 26.27
7) 3.63 (1.11, 6.15) 6.85 (5.26, 8.44) -
51 309 1
8763.78 41209.78 102.02
7) 5.82 (4.22, 7.42) 7.50 (6.66, 8.33) 9.80 (0.00, 29.01)
1) 0.61 (0.28, 1.33) 0.83 (0.62, 1.10) -
1) 0.62 (0.30, 1.31) 0.91 (0.71, 1.18) -
0.2147 0.4926 -
ifying anti-rheumatic drugs (DMARDs) or corticosteroids, in comparison with
eroids, in comparison with matched controls. 3Use of etanercept alone, with or
s the event number and total observed person-years of matched subjects from
es of TNF-α inhibitors and rituximab. HR, hazard ratio; IR, incidence rate; IRR,
Table 3 Death-adjusted multivariate analyses of cancer




Biologics use 0.63 0.49, 0.80 <0.001
Male gender 1.10 0.88, 1.38 0.39
Age at start, per year 1.04 1.03, 1.05 0.000
Disease duration1, per year 0.96 0.94, 0.99 0.02
Number of hospital visits,
per year during observation
1.01 1.01, 1.02 0.000
Methotrexate2 1.04 0.86, 1.26 0.68
Salfulsalazine2 1.01 0.84, 1.20 0.93
Hydroxychloroquine2 1.13 0.94, 1.36 0.19
Corticosteroids2 1.03 0.84, 1.28 0.75
Diabetes mellitus 1.26 0.92, 1.74 0.15
Ischemic heart disease 0.70 0.54, 0.92 0.01
Cerebrovascular disease 0.75 0.45, 1.26 0.28
Hypertension 1.21 0.98, 1.50 0.07
Chronic liver disease 1.16 0.94, 1.42 0.17
Statins3 0.64 0.48, 0.86 0.003
Metformin3 0.67 0.45, 1.00 0.05
NSAIDs3 0.94 0.54, 1.64 0.83
Beta-blocker3 0.77 0.63, 0.93 0.008
1Disease duration represented by duration from the first disease-modifying
anti-rheumatic drugs (DMARDs) prescription for rheumatoid arthritis to the
index date. 2Use of drugs within one year prior to the index date. 3Use of
drugs at least once per month on average during follow-up. 4Modified hazard
ratio adjusted by multiple covariates including age, gender, disease duration,
prior history of hypertension, diabetes, ischemic heart disease, cerebrovascular
disease, chronic liver diseases, use of DMARDs within one year prior to the
index date, corticosteroids, aspirin, non steroidal anti-inflammatory drugs
(NSAIDs), statins and metformin.
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tion to compare the cancer risks of both study groups
with the general population. The cancer risk was signifi-
cantly elevated among subjects in the nbDMARDs co-
hort when compared with the general population, both
for non-hematologic cancers (SIR 1.31, 95% CI 1.19,
1.44) and hematologic cancers (SIR 2.28, 95% CI 1.55,
3.24) (Table 4). On the contrary, the overall cancer risk
for subjects in the biologics cohort was comparable to
that of the general population (SIR 0.97, 95% CI 0.78,
1.19). The overall cancer risk in those taking adalimu-
mab was slightly lower than in those taking etanercept,
either in the patterns of treatment alone, ever-treated or
last-treated with the biologics of interest, yet without stat-
istical significance (Table 4, Additional file 2: Table S2).
However, the risk of hematologic cancer was signifi-
cantly elevated in the biologics cohort when compared
with the general population (SIR 4.64, 95% CI 2.65, 7.53)
(Table 4). The risk of non-Hodgkin’s lymphoma wascomparable between those taking adalimuamb and
those taking etanercept, either in the patterns of treated
alone, ever-treated or last-treated with the biologics of
interest, without statistical significance (Additional file 2:
Table S2).
Discussion
Our study provided nationwide-based evidence that start-
ing TNF-α antagonists does not increase, but rather de-
creases, the risk of cancer for RA patients, in comparison
with those taking nbDMARDs alone, with a reduction in
7-year cumulative incidence from 5.22% to 3.84%. The ef-
fect of TNF-α antagonists was statistically significant
among almost all subgroups of patients. The association
between TNF-α antagonists and cancer risk was inde-
pendent of daily dosage of concomitant nbDMARDs.
Controversy remains with respect to whether biologics
carry a cancer risk for RA patients. A meta-analysis that
included nine RCTs and 5,005 subjects conducted by
Bongartz et al. [15] demonstrated a dose-dependent in-
creased risk of malignancy in RA patients treated with
TNF inhibitors, mainly infliximab and adalimumab. On
the contrary, the most recent systemic review and meta-
analysis from 63 RCTs that included 29,423 patients re-
vealed no statistically significant increased risk of any type
of cancer with use of TNF antagonists plus nbDMARDs,
in comparison with use of nbDMARDs alone [16]. The re-
sults from the British Society for Rheumatology Biologics
Registry for RA patients demonstrated no difference in
risk of solid cancer among patients receiving TNF-α an-
tagonists and patients receiving nbDMARDs over a 5-year
observation period. That study also demonstrated no dif-
ference in the relative risk of cancer for any of the individ-
ual TNF-α antagonists [28]. Two small clinical trials in
Taiwan reported a negative association with short-term
(12-week) risk for cancer in RA patients using etanercept
and adalimumab, compared to RA patients taking metho-
trexate [29,30]. Several other clinical trials have reported
controversial results for long-term cancer risk in subjects
taking TNF-α antagonists, with an observation time of up
to 104 weeks [31-35]. However, half of the trials only in-
cluded subjects with active early RA (less than 2 years).
The association between lymphoma occurrence and use
of biologics in RA has been of major concern [7,17,36,37].
In the present study, we demonstrated a significantly ele-
vated risk of lymphoma in both the biologics cohort and
nbDMARDs cohort when compared with the general
population. Higher risk of lymphoma was observed in the
biologics cohort when compared with the nbDMARDs
cohort, with statistical significance (Table 4, Additional
file 2: Table S2). Data from the MedWatch postmarketing
adverse event surveillance system of the Food and Drug
Administration have revealed an association between
lymphoma and treatment with etanercept or infliximab
Figure 3 Multivariate stratified analyses for cancer occurrence between biologics cohort and biologics-naive cohort. All analyses were
stratified according to age, gender, disease duration, average dosage of corticosteroids or disease-modifying anti-rheumatic drugs (DMARDs) after
the index date, and coexisting comorbidities, based on a modified Cox proportional hazards model in the presence of a competing risk event.
Some hazard ratios (HR) were not statistically significant due to a small number of cases. *Indicates average drug use after the index date of
observation. Event, new cancer occurrence; MI, ischemic heart disease, including myocardial infarction; N, number; CVA, cerebrovascular attack.
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vestigating the safety profiles of adalimumab across several
entities of arthritis have indicated a slightly increased risk
of lymphoma among adalimumab users with RA when
compared with the general population [39]. However, a
study comparing published case reports and reports from
the French pharmacovigilance system has argued the link
between lymphoma and TNF-α antagonists [40]. A pro-
spective cohort study with a large sample size and a long
duration of follow up is required to examine the causality
between biologics and cancer development.
The association between malignant disease and chronic
inflammation is well-documented [41]. We assumed that
patients taking biologics had more severe disease and were
more likely to develop malignant diseases. On the contrary,
the chance of developing cancer was reduced in patients
taking biologics, in comparison with matched patients tak-
ing nbDMARDs only. This implies that the use of biologics
attenuates the disease activity and then reduces the risk ofcancer development to a level that is even lower than in
subjects taking nbMDARDs only.
The mixed effect of concomitant DMARDs may also
affect the risk of cancer. Physicians in Taiwan usually re-
serve low-dose DMARDs in combination with biologics
for reducing the chance of auto-antibody production
and improving clinical outcomes. Our subjects in the bio-
logics cohort received a higher daily dosage of DMARDs
than those in the matched nbDMARDs cohort (Table 1).
These results suggested that patients in the biologics co-
hort have more severe or refractory disease than those in
the nbDMARDs cohort. Further multivariate stratified
analyses suggested that the association between biologics
use and cancer risk is independent of dosage of concomi-
tant non-biologic DMARDs. This further emphasizes the
additional beneficial role of biologics in patients with se-
vere RA.
A low prevalence of RA has been reported in Asian
countries [42-44]. Based on the estimate from the Taiwan
Table 4 Standardized incidence ratio (SIR) of specific cancer types among subjects in the biologics cohort and
nonbiologic DMARDs cohort
Cancer origin Biologics SIR (95% CI) nbDMARDs SIR (95% CI)
N Expected N Expected
Non-hematologic cancers 73 88.46 0.83 (0.65, 1.04) 455 347.47 1.31 (1.19, 1.44)
Oral cavity 2 4.55 0.44 (0.05, 1.59) 20 17.92 1.12 (0.68, 1.72)
Digestive system1 20 32.03 0.62 (0.38, 0.97) 135 125.75 1.07 (0.90, 1.27)
Lungs2 11 10.39 1.06 (0.53, 1.89) 57 40.77 1.40 (1.06, 1.81)
Breast, cervix3 22 19.96 1.10 (0.69, 1.67) 115 78.45 1.47 (1.21, 1.76)
Bladder/kidney4 14 15.75 0.89 (0.49, 1.49) 96 61.81 1.55 (1.26, 1.90)
Melanoma 0 0.21 - 0 0.83 -
NMSC 5 2.43 2.05 (0.66, 4.79) 15 9.58 1.57 (0.88, 2.58)
Unspecified origin 4 5.79 0.69 (0.19, 1.77) 32 22.76 1.41 (0.96, 1.99)
Hematologic cancers5 16 3.45 4.64 (2.65, 7.53) 31 13.57 2.28 (1.55, 3.24)
Lymphoma 13 2.12 6.13 (3.26, 10.49) 21 8.34 2.52 (1.56, 3.85)
NHL 12 2.05 5.86 (3.02, 10.24) 20 8.06 2.48 (1.52, 3.83)
HL 1 0.07 13.97 (0.18, 77.7) 1 0.28 3.56 (0.05, 19.79)
Leukemia 1 1.33 0.75 (0.01, 4.18) 9 5.23 1.72 (0.79, 3.27)
1Cancers of digestive system include cancers of the stomach, colon, liver, pancreas. 2Including cancers of the lungs, bronchus and pleura. 3Including cancers of
the uterus and other female reproductive organs. 4Including cancers of the prostate, testis and other male reproductive organs. 5Myeloma not included.
NbDARDS, nonbiologic disease-modifying anti-rheumatic drugs; HL, Hodgkin’s lymphoma; NHL, non-Hodgkin’s lymphoma; NMSC, non-melanoma skin cancers;
N, number.
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studies, the prevalence of RA is between 0.2 and 0.4% of
the Taiwanese general population [42]. Likewise, the preva-
lence of RA is less than 0.3% in China [43] and decreased
from 0.54% in 1969 to 0.17% in 1996 in Japan [44]. These
prevalence estimates are all much lower than the estimated
1% prevalence in Western countries. The estimate of
prevalence in the present study (approximately 0.2%) is
consistent with that of prior studies in Taiwan. However, as
we included only patients fulfilling all diagnostic criteria
for RA, some patients with very early RA, not registered in
the RCIPD, may not have been included.
The incidence rates of cancer in RA have been re-
ported to be 4.58 in Korea and 6.7 in Taiwan per 1000
patient-years, which are lower than in Western popula-
tions [45,46]. The incidence rates of all-site malignancies
in TNF-α antagonist users in Western populations have
been reported to range from 4.7 to 13 per 1000 patient-
years [18,19,47]. More recently, Mercer et al. reported
the incidence rate of cancer in TNF-α antagonist users
to be 8.1 per 1000 patient-years, compared with 11.7 per
1000 patient-years in nbDMARDs users [28]. The results
from the present study are consistent with those of prior
studies. More epidemiologic studies are required to deter-
mine the cancer prevalence in more Asian populations.
On multivariate analysis, more hospital visits were posi-
tively associated with cancer occurrence. Patients with
more hospital visits were supposed to have more chance
of cancer surveillance. Although there were more hospitalvisits among subjects in the biologics cohort than the
matched nbDMARDs cohort, as presented in Table 1, our
results further reinforced the link between biologics use
and a lower risk of cancer.
Patients with ischemic heart disease (IHD) were found
to have a negative association with cancer occurrence on
multivariate analyses. Patients with IHD tended to have
fatal cardiovascular outcomes and might die too early to
develop a new cancer. After matching comorbidities in
both study cohorts, this bias may happen randomly in
both cohorts. In addition, the medications commonly
used for IHD may play a role in preventing certain can-
cer occurrence or recurrence [48-50]. The negative asso-
ciation is observed independently for use of statins, and
NSAIDs, including aspirin or beta-blockers, on multi-
variate analyses. This link is worth further investigation.
Different study designs would be needed to determine
the role of other anti-hypertensive drugs on cancer risk.
The strengths of the current study include the utilization
of the nationwide NHIRD, which contains detailed phar-
macy claims for each study subject and is widely accepted
for epidemiological studies [3,20,46]. To eliminate immor-
tal time bias, we applied incident user design to this study,
with the exposure time calculated from the start of new bi-
ologics in the biologics group (and corresponding date in
the nbDMARDs group). In addition, we matched both bio-
logics and comparator groups for age, gender, propensity
score, date of first use of DMARDs, and date of first use of
biologics. An active comparator cohort, as was used in this
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long-term disease of similar severity and with similar co-
morbidity index.
There are several limitations to the present study. It is
difficult to infer causation between a drug of interest and
risk of cancer occurrence based on an observational study,
without a random assignment of treatments. Confounding
by indication may exist and account for differences in out-
comes. In addition, the patients in the study cohorts may
differ in many measured and unmeasured ways. We did
not have personal information such as lifestyle, family
history of malignant diseases, body mass index, laboratory
or serologic information, and records of disease severity
score, all of which may contribute to cancer risk. To avoid
these biases, we selected only patients with matched age,
gender, disease duration, and concomitant comorbidities.
Multivariable analysis was performed to adjust for poten-
tial confounders. Furthermore, we conducted multivari-
able stratified analysis to examine the risk of cancer for
the study cohorts in different strata. Although unmeas-
ured confounders may still exist, we believe the method-
ology used in the present study is solid and robust. To
meet the eligibility for biologics use, we selected only sub-
jects free of cancer before taking biologics or the start of
follow up, which may have led to an underestimation of
cancer incidence in both groups.
Coding error is possible in a database. To minimize
this bias, we enrolled only patients from the catastrophic
illness database who met the criteria for RA and malig-
nant diseases. Furthermore, most patients undergo regular
physical and laboratory examination during observation.
A surveillance bias may contribute to an increased fre-
quency of cancer. Our analyses were adjusted for number
of hospital visits to prevent this bias. Some patients may
have used self-paid biologics and thus may have been in-
appropriately classified into the nbDMARDs cohort. This
potential misclassification may have led to an underesti-
mation of the association.
Nonetheless, our study provides important evidence
of the safety, in terms of cancer risk, of anti-TNF-α an-
tagonists in RA patients who survive long-term disease
and who undergo long-term DMARD treatment. In
addition, the potential beneficial effect of biologics was
most significant among those of female gender, those
with long disease-duration and those free of major co-
morbidities. The association between biologics and can-
cer risk was independent of daily dosage of concomitant
nbDMARDs.
The results of our study should be interpreted cau-
tiously because they refer only to two out of five available
TNF-α antagonists. The association between cancer risk
and other TNF-α antagonists needs further analysis.
Moreover, these results refer only to RA patients without
prior malignant diseases. The investigation of the effect ofbiologics on patients with existing malignancy requires a
different study design.
Conclusion
The current study suggested that the addition of anti-
TNF-α therapy is safe, in terms of cancer risk, for RA
patients undergoing long-term DMARD treatment, based
on a Taiwanese nationwide population.
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